With the use of some predictive biomarkers such as PD-L1 to identify those patients who are more likely to acquire a favorable therapeutic effect from exposure to ICIs, the overall effect of cancer immunotherapy has been improved to a certain extent, but there is still a lot of room for improvement. Here, CD274 is linked to cancer.